Your browser is no longer supported. Please, upgrade your browser.
Settings
QURE uniQure N.V. daily Stock Chart
QURE [NASD]
uniQure N.V.
Index- P/E- EPS (ttm)-2.99 Insider Own1.40% Shs Outstand44.28M Perf Week3.14%
Market Cap2.14B Forward P/E- EPS next Y-2.13 Insider Trans-25.91% Shs Float42.01M Perf Month-23.83%
Income-124.40M PEG- EPS next Q-0.67 Inst Own96.10% Short Float10.68% Perf Quarter-11.77%
Sales6.20M P/S345.61 EPS this Y-32.80% Inst Trans2.26% Short Ratio7.77 Perf Half Y-34.27%
Book/sh6.67 P/B7.15 EPS next Y-45.90% ROA-31.40% Target Price75.73 Perf Year-32.17%
Cash/sh7.61 P/C6.27 EPS next 5Y- ROE-45.20% 52W Range36.20 - 76.69 Perf YTD-33.49%
Dividend- P/FCF- EPS past 5Y-1.30% ROI-33.70% 52W High-39.64% Beta1.24
Dividend %- Quick Ratio12.90 Sales past 5Y3.50% Gross Margin- 52W Low27.87% ATR3.34
Employees248 Current Ratio12.90 Sales Q/Q-90.90% Oper. Margin- RSI (14)32.69 Volatility4.74% 5.68%
OptionableYes Debt/Eq0.00 EPS Q/Q14.20% Profit Margin- Rel Volume0.56 Prev Close47.66
ShortableYes LT Debt/Eq0.12 Earnings- Payout- Avg Volume577.02K Price46.29
Recom1.90 SMA20-17.00% SMA50-22.08% SMA200-17.93% Volume231,626 Change-2.87%
Jun-25-20Downgrade Wells Fargo Overweight → Equal Weight $56
Jun-25-20Downgrade Robert W. Baird Outperform → Neutral $58
Jun-25-20Downgrade Mizuho Buy → Neutral $90 → $61
Dec-03-19Initiated Goldman Buy
Dec-03-19Initiated Cowen Outperform
Nov-05-19Initiated Credit Suisse Outperform
Oct-11-19Initiated Stifel Buy
Sep-25-19Initiated Bernstein Outperform $73
Sep-12-19Initiated Mizuho Buy
Jul-30-19Downgrade Guggenheim Buy → Neutral
Jul-08-19Reiterated Cantor Fitzgerald Overweight $81 → $94
Apr-12-19Initiated Piper Jaffray Overweight $80
Mar-29-19Initiated Robert W. Baird Outperform $85
Mar-04-19Reiterated Chardan Capital Markets Buy $70 → $100
Feb-25-19Reiterated Cantor Fitzgerald Overweight $68 → $81
Feb-11-19Reiterated H.C. Wainwright Buy $60 → $73
Dec-31-18Resumed B. Riley FBR Buy $72
Nov-26-18Reiterated H.C. Wainwright Buy $48 → $60
Jul-27-18Initiated Cantor Fitzgerald Overweight $58
Jun-28-18Initiated B. Riley FBR, Inc. Buy $50
Jul-08-20 12:38PM  
Jun-25-20 08:26AM  
07:54AM  
Jun-24-20 06:28PM  
04:05PM  
Jun-19-20 07:05AM  
Jun-17-20 04:05PM  
Jun-15-20 07:05AM  
Jun-01-20 09:29AM  
May-29-20 07:38PM  
May-18-20 07:49AM  
May-14-20 07:00AM  
May-11-20 11:13PM  
Apr-29-20 08:45AM  
07:00AM  
Apr-28-20 04:51PM  
Apr-27-20 12:32PM  
Apr-24-20 04:21PM  
Apr-21-20 10:47AM  
Apr-17-20 07:00AM  
Mar-30-20 07:00AM  
Mar-28-20 09:10PM  
Mar-26-20 12:36PM  
07:00AM  
Mar-18-20 06:01AM  
Mar-03-20 07:00AM  
Mar-02-20 05:45PM  
04:05PM  
04:05PM  
Feb-27-20 07:00AM  
Feb-26-20 08:41AM  
Feb-21-20 10:48AM  
Feb-20-20 12:31PM  
Feb-04-20 07:00AM  
Jan-31-20 07:00AM  
Jan-10-20 02:20PM  
Jan-07-20 12:12PM  
Dec-24-19 09:30AM  
Dec-19-19 10:27AM  
07:00AM  
Dec-17-19 09:11AM  
07:02AM  
06:00AM  
Dec-16-19 09:34AM  
Dec-08-19 04:00PM  
Dec-06-19 09:33AM  
Dec-05-19 04:32PM  
10:12AM  
03:49AM  
Dec-04-19 09:42AM  
Dec-03-19 11:53AM  
Dec-02-19 07:00AM  
Nov-30-19 07:02PM  
Nov-22-19 10:16AM  
Nov-07-19 09:45AM  
Nov-06-19 09:16AM  
Nov-05-19 07:00AM  
Nov-01-19 07:00AM  
Oct-31-19 07:00AM  
Oct-30-19 11:46AM  
10:38AM  
Oct-29-19 12:37PM  
Oct-28-19 08:15AM  
07:00AM  
Oct-25-19 09:15AM  
Oct-02-19 09:33AM  
Oct-01-19 01:43PM  
Sep-30-19 11:10AM  
Sep-27-19 07:00AM  
Sep-26-19 10:34AM  
Sep-05-19 08:39PM  
08:12AM  
Sep-04-19 04:02PM  
Sep-03-19 07:00AM  
Aug-30-19 08:32AM  
07:00AM  
Aug-20-19 07:00AM  
Aug-16-19 06:20AM  
Jul-31-19 06:28AM  
Jul-29-19 08:35AM  
07:18AM  
Jul-26-19 07:00AM  
Jul-19-19 12:15PM  
Jul-11-19 05:33AM  
Jul-09-19 11:07AM  
Jul-08-19 08:19AM  
Jul-06-19 07:00AM  
Jul-02-19 06:02AM  
Jun-29-19 08:25AM  
Jun-22-19 09:33PM  
Jun-21-19 07:00AM  
Jun-20-19 09:41AM  
Jun-19-19 11:20AM  
Jun-18-19 09:15AM  
Jun-17-19 04:21PM  
09:41AM  
09:33AM  
Jun-11-19 08:47AM  
Jun-05-19 11:53AM  
07:08AM  
uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment of hemophilia A; and AMT-190, an IV-administered adeno-associated virus 5-based gene therapy for the treatment of Fabry disease. In addition, it engages in developing AMT-150, a gene therapy candidate for the treatment of Spinocerebellar Ataxia Type 3 disease. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gut RobertChief Medical OfficerJun 23Option Exercise39.1226,8751,051,34472,750Jun 24 04:21 PM
Gut RobertChief Medical OfficerJun 23Sale70.0026,8751,881,25045,875Jun 24 04:21 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJun 17Sale66.047,501495,366303,540Jun 22 04:43 PM
Kapusta Matthew CCEO, CFO, Managing DirectorMay 20Sale59.947,501449,580311,041May 22 05:13 PM
KLEMT CHRISTIANChief Accounting OfficerApr 24Option Exercise26.412,25059,42359,268Apr 28 04:29 PM
KLEMT CHRISTIANChief Accounting OfficerApr 24Sale60.002,250135,00057,018Apr 28 04:29 PM
Kapusta Matthew CCEO, CFO, Managing DirectorApr 22Option Exercise7.539,37670,601327,918Apr 24 04:46 PM
Kapusta Matthew CCEO, CFO, Managing DirectorApr 22Sale56.879,376533,205318,542Apr 24 04:46 PM
Kapusta Matthew CCEO, CFO, Managing DirectorMar 18Option Exercise7.535,62642,364324,168Mar 20 01:16 PM
Kapusta Matthew CCEO, CFO, Managing DirectorMar 18Sale41.485,626233,352318,542Mar 20 01:16 PM
KLEMT CHRISTIANChief Accounting OfficerMar 04Option Exercise26.4115,750415,95872,768Mar 06 10:07 AM
KLEMT CHRISTIANChief Accounting OfficerMar 04Sale52.2915,750823,50057,018Mar 06 10:07 AM
Kapusta Matthew CCEO, CFO, Managing DirectorFeb 19Sale64.567,501484,256284,753Feb 21 10:03 AM
Soteropoulos PaulaDirectorFeb 05Sale60.952,122129,3322,423Feb 05 01:19 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 31Sale57.983,872224,499264,541Jan 31 03:45 PM
Astley-Sparke PhilipDirectorJan 30Sale59.2380747,7996,005Jan 30 09:39 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 30Sale59.3123,5831,398,646268,413Jan 31 03:45 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 29Sale61.9423,5831,460,794291,996Jan 31 03:45 PM
Kuta Alexander Edward IIIExecutive VP, OperationsJan 28Sale62.141,47891,84840,100Jan 30 09:36 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 28Sale61.9223,5831,460,221315,579Jan 29 11:24 AM
Kaye JackDirectorJan 28Sale62.2080650,13314,128Jan 30 09:32 PM
Balachandran MadhavanDirectorJan 28Sale62.2080750,1956,005Jan 30 09:23 PM
Soteropoulos PaulaDirectorJan 28Sale62.1980750,1874,545Jan 30 09:15 PM
van Deventer SanderEVP, Research & Product Dev.Jan 28Sale61.612,227137,21443,127Jan 30 09:11 PM
SCHAFFER DAVIDDirectorJan 28Sale62.2780650,19044,915Jan 30 09:06 PM
KLEMT CHRISTIANChief Accounting OfficerJan 28Sale61.4711,975736,07242,564Jan 30 09:02 PM
Springhorn Jeremy P.DirectorJan 28Sale62.1980750,1906,005Jan 30 08:57 PM
Meek David D.DirectorJan 28Sale62.1972244,9032,508Jan 30 08:54 PM
Gut RobertChief Medical OfficerJan 28Sale62.1959637,06527,885Jan 29 06:02 PM
Gut RobertChief Medical OfficerJan 27Sale60.016,897413,88928,481Jan 29 06:02 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 27Sale65.5528,2891,854,280339,162Jan 29 11:24 AM
Kuta Alexander Edward IIIExecutive VP, OperationsJan 15Option Exercise5.314,00021,24045,578Jan 17 09:39 AM
Kuta Alexander Edward IIIExecutive VP, OperationsJan 15Sale68.974,000275,88041,578Jan 17 09:39 AM
Soteropoulos PaulaDirectorJan 07Sale72.183,000216,5405,352Jan 08 01:48 PM
Kapusta Matthew CCEO, CFO, Managing DirectorDec 18Option Exercise7.537,33955,263374,991Dec 20 04:13 PM
Kapusta Matthew CCEO, CFO, Managing DirectorDec 18Sale70.097,540528,510367,451Dec 20 04:13 PM
Kuta Alexander Edward IIIExecutive VP, OperationsDec 16Option Exercise5.314,00021,24045,578Dec 17 04:09 PM
Kuta Alexander Edward IIIExecutive VP, OperationsDec 16Sale74.594,000298,35641,578Dec 17 04:09 PM
Soteropoulos PaulaDirectorDec 13Option Exercise5.372,00010,74010,352Dec 17 04:06 PM
Soteropoulos PaulaDirectorDec 13Sale70.502,000141,0008,352Dec 17 04:06 PM
Soteropoulos PaulaDirectorDec 09Sale67.502,500168,7508,352Dec 09 06:30 PM
Soteropoulos PaulaDirectorDec 06Sale64.269,082583,60010,852Dec 09 06:30 PM
Kapusta Matthew CCEO, CFO, Managing DirectorNov 20Sale53.748,000429,951367,652Nov 22 10:12 AM
Kuta Alexander Edward IIIExecutive VP, OperationsNov 15Option Exercise5.314,00021,24045,578Nov 19 08:51 AM
Kuta Alexander Edward IIIExecutive VP, OperationsNov 15Sale52.084,000208,31041,578Nov 19 08:51 AM
Kapusta Matthew CCEO, CFO, Managing DirectorOct 23Sale43.228,000345,781375,652Oct 25 08:38 AM
Kuta Alexander Edward IIIExecutive VP, OperationsOct 15Option Exercise5.314,00021,24045,578Oct 17 01:21 PM
Kuta Alexander Edward IIIExecutive VP, OperationsOct 15Sale42.354,000169,40041,578Oct 17 01:21 PM
Gut RobertChief Medical OfficerSep 19Sale47.164,769224,90635,378Sep 20 02:00 PM
Kapusta Matthew CCEO, CFO, Managing DirectorSep 18Sale47.318,000378,486383,652Sep 20 01:49 PM
Kuta Alexander Edward IIIExecutive VP, OperationsSep 16Option Exercise5.314,00021,24030,578Sep 18 01:25 PM
Kuta Alexander Edward IIIExecutive VP, OperationsSep 16Sale47.264,000189,04026,578Sep 18 01:25 PM
Kapusta Matthew CCEO, CFO, Managing DirectorAug 21Sale56.488,000451,840391,230Aug 23 10:43 AM
Astley-Sparke PhilipDirectorAug 01Sale60.126,460388,3446,812Aug 05 12:21 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJul 17Sale71.458,000571,616399,230Jul 19 10:37 AM